PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors - Wikidata - awgldk - TriplyDB

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

http://www.wikidata.org/entity/Q29619686

about

The protein LEM promotes CD8⁺ T cell immunity through effects on mitochondrial respiration Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment The role of pembrolizumab in the treatment of advanced non-small cell lung cancer Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy Immunotherapy for cancer in the central nervous system: Current and future directions Clinical utility of nivolumab in the treatment of advanced melanoma Cancer immunotherapy: the beginning of the end of cancer?Advances in immunotherapy for melanoma Updates in Therapy for Advanced Melanoma Engineering opportunities in cancer immunotherapy CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition Predictive factors for immunotherapy in melanoma Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors Integrating Immune Checkpoint Blockade with Anti-Neo/Mutated Antigens Reactivity to Increase the Clinical Outcome of Immunotherapy Immunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS Sites Melanoma: From Incurable Beast to a Curable Bet. The Success of Immunotherapy The past, present and future of immunotherapy against tumor Strategies and Advancements in Harnessing the Immune System for Gastric Cancer Immunotherapy Materials based tumor immunotherapy vaccines Biomarkers for glioma immunotherapy: the next generation The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity The impact of the myeloid response to radiation therapy Therapeutic cancer vaccines: past, present, and future Pathways and therapeutic targets in melanoma Immunotherapy advances for glioblastoma Combining radiation and immunotherapy: a new systemic therapy for solid tumors?CTLA-4 blockade in tumor models: an overview of preclinical and translational research Optimal management of metastatic melanoma: current strategies and future directions Immunotherapy in the treatment of non-small cell lung cancer Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy Evaluation of current cancer immunotherapy: hemato-oncology The role of regulatory T cells in cancer immunology Innate and adaptive immune cells in the tumor microenvironment Interaction between natural killer cells and regulatory T cells: perspectives for immunotherapy Update on the challenges and recent advances in cancer immunotherapy Tumor infiltrating lymphocytes in ovarian cancer Large molecular systems landscape uncovers T cell trapping in human skin cancer.Nivolumab plus ipilimumab in advanced melanoma.Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy The Future Prospects of Immune Therapy in Gastric and Esophageal Adenocarcinoma

P2860

Q24336998-C38477EB-9641-4F8E-8E82-DE70DB68F612 Q26738359-9FC245CB-B5A6-4FBF-B6C1-F9A2C6D1A94E Q26744076-52C2F0F3-05C9-453B-BB27-4BE4D6FDFE2F Q26745516-0036A2A2-56A8-4CB2-BDD4-9039DB0106CF Q26750765-3A3ABA71-9273-41B4-A80B-6CBC915DBA7B Q26751268-CAF4226F-47F8-4D57-A214-11AE14AEC3E7 Q26752277-C998DFED-202A-4745-BC57-29170F68BA28 Q26768558-8CCF9F50-C74C-47B2-BE52-3F10311A5902 Q26771119-BFB4D6BA-CA0B-4C96-A017-59C0EF59A8FB Q26776373-A7BF7BED-D245-46AD-85D5-459273611637 Q26777563-C7CE3281-71E9-406E-9F38-3086C406E02E Q26778765-EF77EF30-6FAF-4474-88E5-006856F35199 Q26778793-11F858B8-DDAA-463C-B0AD-38A38F8C0C34 Q26783783-B559C88C-2DF7-4095-BCAF-74E4EFDA9968 Q26798402-AB00A1E7-4B48-4945-AD59-8FE61F7EEC3F Q26798404-26C486FB-2775-46C2-A4DF-D99B518D0D6D Q26799896-DDD02373-E57D-4746-9FF6-37BD7D0C3F17 Q26823515-9037FA6A-F3CC-4582-A3F0-C9AD2D8AF83A Q26824135-4CA4082E-0D22-48EB-ACB4-0F8DB70DC5A5 Q26825496-B1CE819D-8B6B-4C3D-BA4A-2F2AB9961FC2 Q26829847-AB9663BE-382D-40EF-A4D5-08ABA4B7CCDA Q26851643-2F15E8AC-4E76-46FA-8CF3-9761962A9A1D Q26863283-4257F615-1A25-4810-9F5E-61A0673A553B Q26865736-71669EEE-A4A4-4455-88F0-AE705C4F2969 Q26866513-7A0F3456-57ED-4146-84FD-460F0004D60C Q26991721-B9466FE9-72CA-4960-A59A-CCC36EF0B9A3 Q26992295-1860CAE3-C7C1-43F8-B866-D61919891C98 Q26997338-D310AE78-0565-42FC-82E0-0F7E404B296A Q27000382-FF4C1495-3EFB-4485-949B-FEE59E7C5896 Q27002646-52A8B7B9-E0C2-442F-8F4D-6F54A0B0D87C Q27006179-CD1F2638-D49F-4967-968B-B50FB7A4F027 Q27006663-22616BAF-6D85-41DC-B311-1945CB28F5BF Q27008342-9BA97B9E-A81B-416C-B7BF-308BC500FB31 Q27008625-E1A49632-0D7F-4015-B8EC-ED91E7C6B37B Q27014693-97D44496-5631-4C3A-9A2F-F756963A081F Q27021878-47A80AD9-B1D9-4019-8E36-D9E108A55440 Q27302197-9C1661D0-1B79-43A9-B315-5419CDDAC18B Q27852310-0530865A-61AC-49B9-8580-BF8E02A292BB Q28066199-2FA03BAF-AE56-475C-A064-2D603583D9C3 Q28069826-6F018CCC-F008-4AA4-B3DA-4752330AAF6B

P2860

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

http://www.wikidata.org/entity/Q29619686

description

2010 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մարտին հրատարակված գիտական հոդված

@hy

article publié dans les Procee ...... f the United States of America

@fr

artículu científicu espublizáu en 2010

@ast

im März 2010 veröffentlichter wissenschaftlicher Artikel

@de

scientific article (publication date: 2 March 2010)

@en

wetenschappelijk artikel (gepubliceerd op 2010/03/02)

@nl

наукова стаття, опублікована в березні 2010

@uk

مقالة علمية (نشرت في 2-3-2010)

@ar

name

PD-1 and CTLA-4 combination bl ...... lls within B16 melanoma tumors

@ast

PD-1 and CTLA-4 combination bl ...... lls within B16 melanoma tumors

@en

type

label

PD-1 and CTLA-4 combination bl ...... lls within B16 melanoma tumors

@ast

PD-1 and CTLA-4 combination bl ...... lls within B16 melanoma tumors

@en

prefLabel

PD-1 and CTLA-4 combination bl ...... lls within B16 melanoma tumors

@ast

PD-1 and CTLA-4 combination bl ...... lls within B16 melanoma tumors

@en

P1433

Q29619686-92230E9B-7690-4A19-990F-FB5071249E1C

P1476

Q29619686-1D9AEDF7-A59C-4C67-9BFF-DD4C930D63FD

P2093

Q29619686-2B9780DB-ADEE-45AA-945B-D7181CA92D47

Q29619686-B2C93AE0-BE6C-411A-B2A8-779023A8AAA2

P2860

Q29619686-032D3AF1-371B-453F-A5C9-6795383720DC

Q29619686-12D32FFE-890C-4BD5-ADBE-C56C5F6C99FE

Q29619686-33208BDA-2344-4832-8771-77E07F14FB8D

Q29619686-3EE8F014-3613-4A58-A1F1-9370B97CE817

Q29619686-46012ABF-8C08-4D7B-AD91-4939D2BAA189

Q29619686-4AD0AF3F-CB68-47D5-9529-862669A77D68

Q29619686-4C25BBD0-E3C1-4B6A-B85E-24DB0D231AFF

Q29619686-548EC306-355C-45EB-925D-B6DC278721D8

Q29619686-62F9EB3E-7C9D-4774-80B5-6D75A0FDEC4E

Q29619686-668E6445-2C32-47A3-ADEB-51C8ED2E8240

P304

Q29619686-2B01F0F4-DCD6-4FA3-9D10-C22954E2984B

P31

Q29619686-8B031ACD-47A6-48C7-829C-4C73E8BD5371

P3181

Q29619686-CE0CCC21-78EB-48F8-9868-3A50872B7606

P356

Q29619686-7F6A88DF-E8EF-4671-BF87-3A2887066730

P407

Q29619686-2F139352-45D9-4D23-8B3D-320FE91039F7

P433

Q29619686-C40AD8E7-360B-4AD8-A0FD-4D3B7A90F5F4

P478

Q29619686-A1F8378B-7A31-4FF4-B264-A7828DE76478

P50

Q29619686-4ca094ea-4255-1623-a974-5db5a8602019

Q29619686-B5E097E6-6951-4D92-A4E1-197DD50D2906

P577

Q29619686-B8DCEB1C-0B94-4673-B8A6-83113A9C6E13

P5875

Q29619686-A638ED01-452F-4370-BB1A-DB023E7F7EFA

P698

Q29619686-B2273269-A279-4A9D-BBC3-F86D34D1C385

P932

Q29619686-5F80F079-7A21-417A-924A-E18A451B9DA8

P3181

P356

PNAS.0915174107

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

PD-1 and CTLA-4 combination bl ...... lls within B16 melanoma tumors

@en

P2093

Hideo Yagita

http://www.w3.org/2001/XMLSchema#string

Welby Montalvo

http://www.w3.org/2001/XMLSchema#string

P2860

CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.

Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal.

Synergistic Reversal of Intrahepatic HCV-Specific CD8 T Cell Exhaustion by Combined PD-1/CTLA-4 Blockade

Myeloid-derived suppressor cells as regulators of the immune system

Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor

Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4

TGF-beta requires CTLA-4 early after T cell activation to induce FoxP3 and generate adaptive CD4+CD25+ regulatory cells.

Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation

Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies.

P304

4275-4280

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

157819

http://www.w3.org/2001/XMLSchema#string

P356

10.1073/PNAS.0915174107

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

107

http://www.w3.org/2001/XMLSchema#string

P50

Michael A. Curran

James P. Allison

P577

2010-02-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41451898

http://www.w3.org/2001/XMLSchema#string

P698

20160101

http://www.w3.org/2001/XMLSchema#string

P932

2840093

http://www.w3.org/2001/XMLSchema#string